The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Development Of Vinorelbine As A Tablet Based Therapy To Cure Ectopic Pregnancies
Funder
National Health and Medical Research Council
Funding Amount
$361,594.00
Summary
Ectopic pregnancies occur if the pregnancy implants in the Fallopian tube. They can be deadly and most are treated surgically. We will examine the exciting possibility that instead of surgery, ectopic pregnancies may be cured with a tablet taken just once. We will perform laboratory studies and a clinical trial, giving vinorelbine to women with ectopic pregnancies.
Soluble Endoglin In The Pathogenesis Of Preeclampsia: Investigation Of Mechanisms And The Development Of Therapeutics
Funder
National Health and Medical Research Council
Funding Amount
$572,733.00
Summary
Preeclampsia is a severe disease of pregnancy. As the pathogenesis is poorly understood, the only treatment is for clinicians to deliver babies irrespective of gestation. We have identified MMP-14 as the molecular scissors that release soluble endoglin from placenta, a toxin centrally responsible for severe preeclampsia. In this project we aim to further investigate the mechanisms governing soluble endoglin release and to begin developing a potential therapeutic for use in the clinic.
Developing Diagnostics And Therapeutics For Preeclampsia: Targeting A Novel Placental Specific SFlt-1 Variant
Funder
National Health and Medical Research Council
Funding Amount
$722,283.00
Summary
Preeclampsia is a dreaded disease of pregnancy, globally responsible for thousands of deaths of mothers and babies. It is caused by a protein called sFlt-1 leaking out of the placenta and attacking the mothers organs. Recently, a new sflt-1 subtype was discovered that is specific to the placenta. It may be the key disease causing toxin in preeclampsia. We will target this placental specific sFlt-1 to generate diagnostics to predict preeclampsia, and explore novel ways to block the toxic effects ....Preeclampsia is a dreaded disease of pregnancy, globally responsible for thousands of deaths of mothers and babies. It is caused by a protein called sFlt-1 leaking out of the placenta and attacking the mothers organs. Recently, a new sflt-1 subtype was discovered that is specific to the placenta. It may be the key disease causing toxin in preeclampsia. We will target this placental specific sFlt-1 to generate diagnostics to predict preeclampsia, and explore novel ways to block the toxic effects of sFlt-1 as a strategy to develop drugs.Read moreRead less
Systematic Screening Approach To Identify New Therapeutics For Preeclampsia
Funder
National Health and Medical Research Council
Funding Amount
$727,529.00
Summary
Preeclampsia is a pregnancy complication where factors are released from the placenta into the mum's bloodstream, causing widespread blood vessel and organ damage. Sadly, there is no treatment. Our laboratory has a set up a system to test whether drugs might be useful as a treatment for preeclampsia. We test whether the drugs decrease the release of these factors and protect blood vessels. In this grant, we propose testing three exciting drug treatments for preeclampsia.
Measuring Hypoxia Induced MRNA In Maternal Blood To Monitor Wellbeing Of Growth-restricted Fetuses
Funder
National Health and Medical Research Council
Funding Amount
$421,358.00
Summary
Severely growth restricted fetuses are at peril of stillbirth from low oxygenation. While ultrasound monitoring improves outcomes, babies are still lost. Better ways to monitor the health the unborn baby are needed. We have recently discovered fetuses’ starved of oxygen leak RNA into mother's blood. Thus, measuring RNA molecules in blood could be used to assess fetal health. We will examine whether measuring mRNA in maternal blood could be used to monitor wellbeing of growth-restricted fetuses.
This project will substantially improve our understanding of the potential causes of vascular complications of pregnancy including preeclampsia, and provide a solid foundation to develop new clinical interventions for women who develop this disease during their pregnancy. It will also investigate if a peptide hormone, relaxin, could be an effective treatment to manage the health of women diagnosed with preeclampsia during their pregnancy and prevent delivery of severely premature infants.
M-PreM Study: Reproductive Factors, From Menarche To Pre-menopause, And The Risk Of Cardiometabolic And Respiratory Conditions Before Menopause
Funder
National Health and Medical Research Council
Funding Amount
$1,366,831.00
Summary
This study will investigate links between reproductive factors and body size of premenopausal women with their risk of major chronic conditions, such as cardiovascular disease, diabetes, and asthma. It builds on two decades of survey data from Australia’s flagship study of women’s health with a new biomedical assessment. Findings will guide the use of indicators of women’s reproductive health as a trigger for early and targeted approaches for chronic disease prevention.
New Generation Antiplatelet Therapies To Prevent Preeclampsia
Funder
National Health and Medical Research Council
Funding Amount
$483,148.00
Summary
Preeclampsia, a major complication of pregnancy, affects around 3-8% of pregnancies. Sadly, there is no way to prevent or delay disease. We have uncovered antiplatelet agents, used to prevent heart disease and stroke, may provide health benefits to women at risk of developing preeclampsia. We will test whether these agents can prevent the pathophysiology of preeclampsia in specialized human & mouse models developed in our laboratory. This work may provide a prevention strategy for preeclampsia.
From Pathogenesis To Therapeutics: Targeting Two Signalling Pathways As A Therapeutic Strategy To Treat Preeclampsia
Funder
National Health and Medical Research Council
Funding Amount
$499,048.00
Summary
Preeclampsia is a serious complication of pregnancy that claims the lives of thousands of mothers and babies each year. There is no efficacious medical treatment besides delivery of the baby and placenta. Our lack of therapeutics is largely a result of our poor understanding of the disease. In this application we plan to thoroughly characterise two pathways we believe responsible for preeclampsia, effectively identifying many points at which new therapies could be targeted.
Modifying The Trajectory Of Insidious Late Life Cognitive Decline Using Computerised Cognitive Training
Funder
National Health and Medical Research Council
Funding Amount
$743,152.00
Summary
Supervised, group-based computerised cognitive training (CCT) is a safe and effective intervention to maintain cognition in healthy older adults. This project will examine the extent to which CCT can attenuate or even reverse the rate of decline in older people with previously documented cognitive decline, as well as strategies to maintain CCT effects in the long term.